submit a description of how such payments 
are calculated along with the information 
submitted under section 1860D–11(b). 
Such description shall be submitted at the 
same time and in a similar manner to the 
manner in which the information described 
in paragraph (2) of such section is sub-
mitted.’’; and 
(D) by adding at the end the following new 
subparagraph: 
‘‘(F) 
PHARMACY
ACCESS
REQUIRE-
MENTS.—The PDP sponsor of a prescription 
drug plan shall secure the participation in its 
network of a sufficient number of retail phar-
macies to assure that enrollees have the option 
of obtaining services under the medication ther-
apy management program under this paragraph 
directly from community-based retail phar-
macies.’’. 
(2) EFFECTIVE DATE.—The amendments made 
by this subsection shall apply to medication therapy 
management services provided on or after January 
1, 2008. 
(b) MEDICATION
THERAPY
MANAGEMENT
DEM-
ONSTRATION PROGRAM.—Section 1860D–4(c) of the So-
VerDate Aug 31 2005 
00:08 Jul 18, 2007
Jkt 059200
PO 00000
Frm 00076
Fmt 6652
Sfmt 6201
E:\BILLS\H3025.IH
H3025
ccoleman on PROD1PC71 with BILLS
cial Security Act (42 U.S.C. 1395w–104(c)) is amended 
by adding at the end the following new paragraph: 
‘‘(3) COMMUNITY-BASED MEDICATION THERAPY 
MANAGEMENT DEMONSTRATION PROGRAM.— 
‘‘(A) ESTABLISHMENT.— 
‘‘(i) IN GENERAL.—By not later than 
January 1, 2008, the Secretary shall es-
tablish a 2-year demonstration program, 
based on the recommendations of the Best 
Practices Commission established under 
subparagraph (B), with both PDP spon-
sors of prescription drug plans and Medi-
care Advantage Organizations offering 
MA–PD plans, to examine the impact of 
medication therapy management furnished 
by a pharmacist in a community-based or 
ambulatory-based setting on quality of 
care, spending under this part, and patient 
health. 
‘‘(ii) SITES.— 
‘‘(I) IN
GENERAL.—Subject to 
subclause (II), the Secretary shall 
designate not less than 10 PDP spon-
sors of prescription drug plans or 
Medicare Advantage Organizations of-
VerDate Aug 31 2005 
00:08 Jul 18, 2007
Jkt 059200
PO 00000
Frm 00077
Fmt 6652
Sfmt 6201
E:\BILLS\H3025.IH
H3025
ccoleman on PROD1PC71 with BILLS
fering MA–PD plans, none of which 
provide prescription drug coverage 
under such plans in the same PDP or 
MA region, respectively, to conduct 
the demonstration program under this 
paragraph. 
‘‘(II) DESIGNATION CONSISTENT 
WITH
RECOMMENDATIONS
OF
BEST 
PRACTICES
COMMISSION.—The Sec-
retary shall ensure that the designa-
tion of sites under subclause (I) is 
consistent with the recommendations 
of the Best Practices Commission 
under subparagraph (B)(ii). 
‘‘(B) BEST PRACTICES COMMISSION.— 
‘‘(i) ESTABLISHMENT.—The Secretary 
shall establish a Best Practices Commis-
sion composed of representatives from 
pharmacy organizations, health care orga-
nizations, beneficiary advocates, chronic 
disease groups, and other stakeholders (as 
determined appropriate by the Secretary) 
for the purpose of developing a best prac-
tices model for medication therapy man-
agement. 
VerDate Aug 31 2005 
00:08 Jul 18, 2007
Jkt 059200
PO 00000
Frm 00078
Fmt 6652
Sfmt 6201
E:\BILLS\H3025.IH
H3025
ccoleman on PROD1PC71 with BILLS
‘‘(ii) RECOMMENDATIONS.—The Com-
mission shall submit to the Secretary rec-
ommendations on the following: 
‘‘(I) The minimum number of en-
rollees that should be included in the 
demonstration program, and at each 
demonstration program site, to deter-
mine the impact of medication ther-
apy management furnished by a phar-
macist in a community-based setting 
on quality of care, spending under 
this part, and patient health. 
‘‘(II) The number of urban and 
rural sites that should be included in 
the demonstration program to ensure 
that prescription drug plans and MA– 
PD plans offered in urban and rural 
areas are adequately represented. 
‘‘(III) A best practices model for 
medication therapy management to be 
implemented under the demonstration 
program under this paragraph. 
‘‘(C) REPORTS.— 
‘‘(i) INTERIM
REPORT.—Not later 
than 1 year after the commencement of the 
VerDate Aug 31 2005 
00:08 Jul 18, 2007
Jkt 059200
PO 00000
Frm 00079
Fmt 6652
Sfmt 6201
E:\BILLS\H3025.IH
H3025
ccoleman on PROD1PC71 with BILLS
demonstration 
program, 
the 
Secretary 
shall submit to Congress an interim report 
on such program. 
‘‘(ii) FINAL REPORT.—Not later than 
6 months after the completion of the dem-
onstration program, the Secretary shall 
submit to Congress a final report on such 
program, together with recommendations 
for such legislation and administrative ac-
tion as the Secretary determines appro-
priate. 
‘‘(D) WAIVER AUTHORITY.—The Secretary 
may waive such requirements of titles XI and 
XVIII as may be necessary for the purpose of 
carrying out the demonstration program under 
this paragraph.’’. 
Æ 
VerDate Aug 31 2005 
00:08 Jul 18, 2007
Jkt 059200
PO 00000
Frm 00080
Fmt 6652
Sfmt 6301
E:\BILLS\H3025.IH
H3025
ccoleman on PROD1PC71 with BILLS